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ABSTRACT   
Nephrolithiasis (NL) and nephrocalcinosis (NC), which comprise renal calcification of 
the collecting system and parenchyma, respectively, have a multi-factorial etiology with 
environmental and genetic determinants, and affect ~10% of adults by 70 years of age. 
Studies of families with hereditary NL and NC have identified >30 causative genes which 
have increased our understanding of extracellular calcium homeostasis and renal tubular 
transport of calcium. However, these account for <20% of the likely genes that are 
involved and to identify novel genes for renal calcification disorders we investigated 
1,745 12-month old progeny from a male mouse that had been treated with the chemical 
mutagen, N-ethyl-N-nitrosourea (ENU), for radiological renal opacities. This identified a 
male mouse with renal calcification which was inherited as an autosomal dominant trait 
with >80% penetrance in 152 progeny. The calcification consisted of calcium phosphate 
deposits in the renal papillae and was associated with the presence of the urinary 
macromolecules osteopontin and Tamm-Horsfall protein, which are features found in 
Randall’s plaques of patients with NC. Genome-wide mapping located the disease locus 
to a ~30Mbp region on chromosome 17A3.3-B3 and whole-exome sequence analysis 
identified a heterozygous mutation, resulting in a missense substitution (Met149Thr, 
M149T), in the bromodomain containing protein 4 (BRD4). The mutant heterozygous 
(Brd4+/M149T) mice, when compared to wild-type (Brd4+/+) mice, were normocalcemic 
and normophosphatemic, with normal urinary excretions of calcium and phosphate, and 
had normal bone turnover markers. BRD4 plays a critical role in histone modification and 
gene transcription, and cDNA expression profiling, using kidneys from Brd4+/M149T and 
Brd4+/+ mice, revealed differential expression of genes involved in vitamin D 
metabolism, cell differentiation and apoptosis. Kidneys from Brd4+/M149T mice also had 
increased apoptosis at sites of calcification within the renal papillae. Thus, our studies 
have established a mouse model, due to a Brd4 Met149Thr mutation, for inherited NC. 
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INTRODUCTION 
Renal calcification may occur in the kidney parenchyma (nephrocalcinosis (NC)) or the 
collecting system (nephrolithiasis (NL), i.e. kidney stones)(1-4). NL and NC affect ~10% 
of the adult Western population by the age of 70 years(1-3), although such distinctions may 
be difficult in patients who may develop both NL and NC, and it has been reported that 
>50-70% of patients with kidney stones will have NC(5). The renal calcification in NL 
and NC, results from deposition of calcium oxalate and calcium phosphate(4), which has a 
multifactorial etiology that involves environmental and genetic causes, and may also be 
associated with several endocrine and metabolic disorders including primary 
hyperparathyroidism, hypercalciuria, renal tubular acidosis, cystinuria, low urinary 
volume and hyperoxaluria(1,6). Hypercalciuria is the commonest metabolic abnormality 
associated with NL and NC; however around 30% of individuals with kidney stones have 
been reported to have no obvious underlying metabolic defect (idiopathic NL)(1,6-8). NL, 
NC and hypercalciuria are likely to have a genetic basis as up to 65% of kidney stone 
patients have been reported to have an affected family member(9,10) and twin studies have 
estimated that the heritability of hypercalciuria(11) and kidney stones(12) is >50% and 
>55%, respectively. Moreover, studies of families with rare monogenic disorders 
associated with hypercalciuric NL and NC, such as Bartter’s syndrome, Dent’s disease, 
autosomal dominant hypocalcaemia, and distal renal tubular acidosis have identified 
mutations in >30 genes involved in the regulation of calcium transport (Table S1)(3,13,14). 
Furthermore, genome-wide association studies and targeted sequencing of genes with 
known roles in calcium and vitamin D metabolism have reported associations for NL and 
NC with common sequence variants in >10 additional genes (Table S1)(2,15-17). However, 
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these account for only ~15-20% of cases(3,13), and the identification of further monogenic 
causes of NL and NC are limited by the availability of large families. To overcome this 
and to facilitate further positional cloning studies to discover other genes regulating renal 
calcification, we undertook an X-ray screen of first generation (G1) offspring of mice 
treated with the chemical mutagen N-ethyl-N-nitrosourea (ENU)(18), for renal opacities, 
with the aim of identifying mice with renal calcium deposits, as calcium-containing 
stones are the most common type of kidney stones. ENU is an alkylating agent that 
causes germ-line point mutations with a frequency as high as 0.015 mutations/locus(19). 
Such mutations may result in loss-of-function, hypomorphic, hypermorphic and 
dominant-negative changes in protein function, thus making the ENU mouse mutagenesis 
resource a useful tool for generating novel genetic models of human disease(18,19). Here, 
we describe a mouse model for autosomal dominant renal calcification, designated 
RCALC type 1 (RCALC1), identified from this ENU screen, which is associated with a 
Met149Thr missense mutation in the gene encoding bromodomain containing protein 4 
(Brd4).  
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MATERIALS AND METHODS 
Experimental Animals 
ENU-treated G0 BALB/cAnNCrl male mice were mated to C3H/HeH (C3H) females to 
produce G1 progeny. Male G1 offspring were X-rayed for renal opacities and sperm 
archived, as previously described(20,21). Archived sperm from the founder male with renal 
calcification (Fig. 1A) was used for in vitro fertilisation (IVF) of C3H oocytes to derive 
G2 animals for inheritance testing and genetic mapping studies(20). Mice were fed on a 
standard diet (Rat and Mouse number 3, Special Diet Services, Essex, UK) that contained 
1.15% calcium, 0.58% phosphate, and 4089 IU/kg of vitamin D, and provided with 
water ad libitum(22). All animal studies were carried out using guidelines issued by the 
UK Medical Research Council in Responsibility in Use of Animals for Medical Research 
(July 1993) and UK Home Office project licence numbers (30/2250 and 30/2752).   
 
Metabolic cage studies, plasma and urine biochemistry 
Sixteen-week-old G2 mice were individually housed in metabolic cages (Techniplast, 
Louviers, France) for 5 days with free access to food and water(23). Mice were weighed 
before and after the study, and food and water intake were monitored. Twenty-four-hour 
urine samples were collected in the presence of sodium azide and blood samples were 
collected from lateral tail vein or the internal jugular vein in lithium heparin Microvette 
tubes (Sarstedt, Leicester, UK) following terminal anaesthesia, as previously 
described(23). Plasma and/or urine were appropriately analyzed for sodium, potassium, 
chloride, total calcium, phosphate, urea, glucose, creatinine, magnesium, urate, citrate, 
total protein, albumin and alkaline phosphatase activity on a Beckman Coulter AU680 
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analyzer, as previously reported(21,22). Plasma calcium was adjusted for variations in 
albumin concentrations using the formula: (plasma calcium (mmol/L) − [(plasma albumin 
(g/L) − 30) × 0.02]), as reported(22). Plasma PTH was measured using a two-site ELISA 
specific for mouse intact PTH (Immutopics)(22). Plasma concentrations of 25-
hydroxyvitamin D (25OHD) and Procollagen type 1 N-terminal propeptide (P1NP), and 
also urinary concentrations of serum C-telopeptide (CTx) were measured by enzyme 
immunoassay (EIA) (Immunodiagnostic Systems)(24,25). Urine pH was measured using a 
pH 211 meter (Hanna Instruments)(26). A Kruskal-Wallis test was undertaken for multiple 
comparisons, and any significant differences identified were further assessed using the 
Dunn’s test for nonparametric pairwise multiple comparisons. All analyses were 
undertaken using GraphPad Prism software, and a value of p<0.05 was considered 
significant. 
 
Kidney histology and immunofluorescence 
Kidneys were dissected from 16-18 week old mice, halved, fixed in 10% neutral-buffered 
formalin overnight, and embedded in paraffin wax. Four-µm serial sections were 
prepared and stained with haematoxylin and eosin (H&E), and von Kossa, which reacts 
with the phosphate moiety of calcium phosphate(27), as described previously(20). Images 
were collected on a Nikon Eclipse E400 microscope (Kingston-upon-Thames, UK), 
equipped with a Nikon DXM1200C digital camera. Slides were examined by two 
independent observers, by light microscopy using 10x and 20x objective lenses to 
confirm the presence of renal calcification. Each observer was blinded to the 
experimental group and in cases in which there was disagreement a third investigator 
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reviewed the slide and made the final decision. Coincident calcification on at least two 
serial sections was accepted as positive, and the H&E stained sections were then 
examined under polarized light for possible birefringence, that would indicate the 
presence of calcium oxalate crystals in the depositions(27), using a Zeiss Axiocam MRc 
(Cambridge, UK) camera, with a pixel size of 6.7 μm and a 1300 x 1030 pixel field of 
view equivalent to an area of 8.7 mm x 6.9 mm, that was adapted for polarised light 
microscopy with plan semi-apochromat 10x/NA 0.3 and 20x/NA 0.35 LWD objectives. 
Pizzolato staining to detect calcium oxalate was performed as described(28). Briefly, 4μm 
kidney serial sections were deparaffinised, rehydrated, then incubated in a solution of 
equal quantities of 5% silver nitrate and 30% hydrogen peroxidase under a 60-watt light 
bulb. Sections were then counterstained with nuclear fast red. Osteopontin 
immunohistochemistry was performed on deparaffinised, rehydrated 4µm kidney sections 
following antigen retrieval using an anti-osteopontin rabbit polyclonal antibody (L-175, 
kind gift from LW Fisher, NIH, Maryland, USA)(29),  followed by an Alexa Fluor 488-
conjugated donkey anti-rabbit antibody (Molecular Probes, Hilden, Germany). Tamm-
Horsfall protein (THP) staining was performed using sheep anti-THP (Biodesign 
International, Maine, USA), followed by a secondary detection using Cy3-conjugated 
donkey anti-sheep antibody (Jackson ImmunoResearch, Newmarket, UK). Controls were 
performed without a primary antibody, and showed no staining.  
 
Terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) to detect 
apoptotic cells was performed using the ApopTag Fluorescein In Situ Apoptosis 
Detection kit (Millipore, Watford, UK) according to the manufacturer’s instructions. 
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Stained sections were mounted in Vectashield containing DAPI (Vector Labs, 
Peterborough, UK) visualised by epifluorescence microscopy and a Nikon DXM1200C 
digital camera. The NIS-Elements BR 2.30 software was used to estimate the number of 
TUNEL positive cells per 1000 DAPI positive cells. Statistical comparisons for TUNEL 
staining was performed using the Fisher’s exact test and χ2 test with Yate’s correction. 
 
Genetic Mapping 
Genomic DNA was isolated from tail biopsies using the Gentra PureGene kit (Qiagen, 
Manchester, UK) and genome-wide scans performed by pyrosequencing(30) using a panel 
of 59 informative SNPs distributed across 19 autosomes, at 20-30cM intervals. 
Polymorphic positions were analyzed using a PSQ-96 system (Qiagen)(20). Chromosomal 
linkage was verified by non-inheritance of BALB/c alleles of SNPs of interest in 13 
unaffected littermates. G2 and G3 mice were genotyped for additional markers within the 
critical region. 
 
Exome sequence analysis 
Sequencing libraries were constructed using the NimbleGen kit (Roche, West Sussex, 
UK) and libraries combined in pools of six for targeted capture, using the SeqCap EZ 
Mouse Exome SR v2.2 (target regions available from 
ftp://ftp.jax.org/Genome_Biology_mouse_exomes). Libraries were assessed pre- and 
post-capture for quality and yield, using a High Sensitivity DNA assay (Agilent, Santa 
Clara, California) and Library Quantification Kit (Kapa Biosystems, Gillingham, UK). 
Massive parallel sequencing was performed with 6 samples per flow cell lane, using the 
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HiSeq2000 platform and SBS reagents (Illumina, San Diego, California) to generate 
100bp paired-end reads. Illumina Data Analysis Pipeline software (CASAVA 1.8.1) was 
used for initial base calling and data multiplexing.  Illumina reads were mapped to the 
mouse genome (mm9) using the Burrows-Wheeler Aligner (BWA)_v2(31) with the default 
parameters. Single nucleotide variant (SNV) calls were made using a customised version 
of The Genome Analysis Toolkit (GATK)(32) with default parameters. Several triaging 
steps were made to reduce false positives(33). The 17 Mouse Genome dataset(34) was used 
to filter inbred single nucleotide polymorphism (SNPs) sites from the RCALC1 SNV 
dataset, and common sites were removed from further investigation. The remaining 
SNVs were further filtered by removing sites with an allele frequency <35% and >80%, a 
read depth <3 and a quality score <200.  The final RCALC1 SNV dataset was annotated 
with NGS-SNP(35).  
 
DNA sequence analysis, protein sequence alignment and protein prediction 
Variants were validated in G2 mice by Sanger DNA sequencing, using appropriate gene-
specific primers (Sigma, Gillingham, UK), followed by dideoxynucleotide sequencing 
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, 
California) and an automated detection system (ABI3730 capillary sequencer; Applied 
Biosystems, Carlsbad, California)(36). Protein sequences were aligned using ClustalW(20). 
MutationTaster (http://www.mutationtaster.org/) was used to predict the effects of 
mutations(37). BRD4 modeling was undertaken using the BRD4 structure in complex with 
an extracellular signal-regulated kinase 5 inhibitor (PDB: 5LRQ), and figures prepared 
using the PyMOL Molecular Graphics System, Schrodinger (https://pymol.org/).  
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 RNA extraction, cDNA Expression Profiling and quantitative RT-PCR (qRT-PCR)  
Total RNA was extracted from whole kidney samples taken from >16 week-old 
RCALC1, or parental wild-type (WT) BALB/c and C3H mice (N= 4 mice per group) 
using Trizol reagent (Invitrogen, Carlsbad, CA). Following DNaseI-treatment, RNA was 
purified using an RNeasy Mini kit (Qiagen). Nine-µg total RNA was used for first and 
second-strand cDNA synthesis using the One-Cycle cDNA Synthesis Kit (Affymetrix, 
High Wycombe, UK) according to the manufacturer’s instructions. Biotinylated cRNA 
was synthesized using the Genechip IVT Labelling Kit (Affymetrix). Fifteen-µg of 
fragmented cRNA was hybridized for 16 hours at 45°C to Mouse Genome 430 2.0 arrays 
(Affymetrix). Following hybridization, arrays were washed and stained with streptavidin-
phycoerythrin in the Affymetrix Fluidics Station 450 and scanned using the GeneChip 
Scanner 3000 7G. The image data were analyzed with GCOS 1.4 using Affymetrix 
default analysis settings and global scaling as a normalization method. The dataset of the 
arrays were normalized using Robust Multi-chip Average algorithm in respect to the 
sequence-specific probe affinities(38). Probesets with marginal expression (maximum 
native signal <50) were removed and the remaining 17,811 probe sets were analyzed 
using the F-test. After ANOVA false discovery rate (FDR) multiple testing 
corrections(39), individual differences between the datasets were investigated using the 
least significant difference (LSD) posthoc test. Genes with >1.5-fold difference in 
expression (in the same direction) vs. both parental strains were selected for further 
investigation. qRT-PCR reactions were performed in kidney samples from 4-5 mice using 
the QuantiTect SYBR Green Kit (Qiagen) and a Rotorgene 5 (Qiagen), as previously 
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described(40). All qRT-PCR test samples were normalized to the geometric mean of three 
housekeeper genes (cyclin D1 (Ccnd1), cyclin D2 (Ccnd2), and glyceraldehyde 3-
phosphate dehydrogenase (Gapdh)), as described previously)(40). All primers were 
obtained from Quantitect (Qiagen). Threshold cycle (CT) values were obtained from the 
start of the log phase on Rotorgene Q Series Software and CT values analyzed in 
Microsoft Excel 97–2010 using the Pfaffl method(40,41). Data for RCALC1 mice were 
expressed relative to wild-type littermates, which were set at 1. Statistical analyses were 
performed using the Student’s t-test.   
 
Statistical analysis 
Statistical analyses were performed using the Kruskal-Wallis test, Dunn’s test for 
nonparametric pairwise multiple comparisons, Fisher’s exact test, χ2 test with Yate’s 
correction, Student’s t-test, the F-test, and LSD posthoc tests.  
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RESULTS 
Identification and characterization of mice with autosomal dominant renal 
calcification (RCALC1)  
A radiological screen of 1,745 12-month old G1 male offspring of ENU-treated BALB/c 
males and wild-type (WT) C3H/HeH (C3H) females was performed to detect renal 
opacities. This identified a male with a single opacity in the region of the left kidney (Fig. 
1A). To confirm genetic transmission of the phenotype of renal calcification, 152 second-
generation (G2) backcross mice (69 males, 83 females) were derived by in vitro 
fertilisation (IVF) of WT C3H oocytes using sperm archived from this founder G1 male 
with renal calcification. These G2 mice were assessed at 16-18 weeks of age by renal 
histology, as renal opacities could not be detected by X-ray in mice of this age range.  
Renal histology was performed using sections stained with H&E (Fig. S1) and von Kossa 
stain (Fig. 1B-E), which specifically reacts with the phosphate moiety of calcium 
phosphate deposits(27), and polarized light microscopy to assess for birefringence due to 
calcium oxalate crystals (Fig. S1), This approach was used as calcium phosphate and 
calcium oxalate crystals can be distinguished by their tinctorial properties(27). Thus, on 
H&E  stained sections, calcium phosphate deposits may appear blue or purple (Fig. S1), 
whereas calcium oxalate deposits are translucent; whilst sections treated with von Kossa 
stains reveal calcium phosphate, but not calcium oxalate crystals as dark brown or black 
deposits (Fig. 1B-E, Fig. S1); whereas only calcium oxalate, but not calcium phosphate, 
crystals are birefringent under polarized light(27). This analysis showed that the renal 
calcification in the G2 mice consisted of calcium phosphate, as the deposits were: blue-
purple on H&E sections (Fig. S1); and deep brown-black on von Kossa stained sections 
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(Fig. 1B-C and Fig. S1). Moreover, the renal calcification was not birefringent under 
polarized light (Fig. S1), thereby indicating that it did not contain calcium oxalate 
crystals, and this was confirmed by use of Pizzolato staining and observing a lack of 
brown-black deposits(28) (Fig. S1).  
 
The calcification, due to calcium phosphate deposits was observed to occur in the renal 
cortex and papilla of the G2 mice (Fig. 1B-C). However, spontaneous renal calcification 
has been reported to occur in WT C3H mice(42,43), and to minimise confounding 
influences on the phenotype of renal calcification from the WT C3H strain we further 
characterized the locations of the renal calcification by von Kossa staining using kidney 
sections from WT C3H mice at 16 weeks of age (10 males, 10 females). In the WT C3H 
mice, the renal calcification was found to be present within the cortex of all 20 pairs of 
kidneys, but calcification within the renal papilla was found to be present in only one 
mouse (i.e. 5% of mice) (Fig. 1D-E). This calcification in the renal papilla of the WT 
C3H mouse was identified within the intracellular compartment of collecting duct cells 
(Fig. 1E). Therefore, G2 mice with calcification of the renal cortex or intracellular 
collecting duct cells were classified as being unaffected, as the calcification was not 
different to that observed in the WT C3H mice, and G2 mice having renal calcification 
specifically within the interstitial regions of the renal papilla (Fig. 1C), were classified as 
having the RCALC1 phenotype. Using these criteria, seventy (26 males, 44 females) of 
the 152 G2 mice (i.e. 46%) were found to have calcification within the interstitial regions 
of the renal papilla, consistent with an autosomal dominant disorder, in which ~50% of 
progeny would be affected. In addition, the ratio of affected males to affected females 
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was not significantly different to the expected 1:1 ratio of affected males (M) and females 
(F) (i.e. 26M:44F versus 35M:35F, χ2-test, p=0.125) for an autosomal dominant disorder. 
The ratio of WT (i.e. unaffected) males:females = 39M to 43F was also not significantly 
different to the expected 1:1 ratio (i.e. 41M:41F, χ2-test, p=0.871), for an autosomal 
dominant trait.  
 
The RCALC1 phenotype has similarities to human NC, which includes the interstitial 
deposition of calcium phosphate  in the renal papillae(4,44,45). For example, high resolution 
Fourier transform infrared microspectroscopy and electron diffraction studies have 
revealed that calcium phosphate crystals are the major component of Randall’s plaque, 
which are the areas of the renal papillae that contain interstitial calcium phosphate 
deposits that provide a nidus of urothelial surface for calcium oxalate 
deposition(4,6,16,46,47). Moreover, immunohistological examinations of renal biopsies from 
patients with kidney stones, have shown the presence of the urinary macromolecules 
osteopontin and THP in association with Randall’s plaques(44,45,48), and to explore the 
similarities between the RCALC1 and human NC histological phenotypes, we therefore 
investigated serial sections of kidneys from the RCALC1 mice and WT littermates for 
such abnormalities using immunofluorescence to detect osteopontin and THP, and von 
Kossa staining to detect calcification. This revealed the presence of osteopontin in the 
areas of interstitial calcification within the renal papillae of RCALC1 mice (Fig. 1F-G), 
and this was absent in the renal papillae of WT littermates (Fig. 1H-I) (n=4; 2-tailed 
Fisher’s Exact test, p<0.01). Moreover, THP, which was found to be present in the thick 
ascending limb of Henle in RCALC1 and WT kidneys (Fig. 1J and 1L), was also 
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localised to the interstitial space of the renal papilla in RCALC1 mice (Fig. 1J) where it 
colocalized with calcified areas that were revealed by von Kossa staining (Fig. 1J-K). 
Interstitial THP immunostaining was not detected in the renal papilla of WT mice (Fig. 
1L-M). Therefore, RCALC1 mice have calcification due to calcium phosphate deposition 
of the renal papilla, which contains osteopontin and THP, and these findings are similar 
to those observed in patients with NC(4,46).  
 
Mapping of the RCALC1 locus to chromosome 17A3.3-B3 and identification of the 
Brd4 missense mutation by whole-exome sequence analysis 
Genome-wide analysis using a panel of 59 informative SNPs and DNA from 13 G2 mice 
with renal papillary calcification (i.e. the RCALC1 phenotype) mapped the RCALC1 
locus to a ~30Mbp region on chromosome 17 A3.3-B3 between rs33663699 and 
D17Mit115 (LOD=3.91, 0% recombination) (Fig. 2A). Further mapping studies using 11 
additional genetic markers (8 microsatellite markers and 3 SNPs) within this candidate 
interval in an additional 38 G2 RCALC1 mice (total number of 51 mice studied) revealed 
the renal calcification phenotype co-segregated with BALB/c alleles between rs33663699 
and D17Mit51 (Fig. 2A). Co-segregation of the RCALC1 phenotype with markers in this 
chromosome 17A3.3-B3 interval was confirmed in up to 4 generations. Finally, 26 of the 
152 G2 mice (i.e. 17%), with the BALB/c haplotypes for the chromosome 17 markers, 
were phenotypically normal (i.e. did not have renal papillary calcification), thereby 
indicating an 83% penetrance for this phenotype in >16 week-old G2 mice. 
 
The interval between rs33663699 and D17Mit115 that encompasses the RCALC1 locus 
contains over 500 genes, and to identify the RCALC1 causative gene, we performed 
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whole-exome sequence analysis in two G2 RCALC1 mice with renal papillary 
calcification, as well as one WT BALB/c mouse and one WT C3H mouse, in order to 
determine inheritance of the variants from the parental mice. This analysis identified 20 
unique variants, of which three were located on chromosome 17, but only one of these, 
which involved the bromodomain containing protein 4 (Brd4) gene, was within the 
interval containing the RCALC1 locus (Table S2). This variant was a non-synonymous 
heterozygous T-to-C transition at nucleotide c.446 in the Brd4 gene. The T-to-C 
transition in codon 149 of Brd4 is predicted to cause a missense amino acid change from 
Met149 to Thr149 (Met149Thr, M149T) (Fig. 2B). Further analysis of the G2 mice (total 
= 152), by Sanger DNA sequencing (Fig. 2B), revealed that 66% of the mice with renal 
papillary calcification were heterozygous for the Brd4 variant (Brd4+/M149T), and 74% of 
mice without renal papillary calcification were homozygous for the WT allele (Brd4+/+) 
(Table 1). Extension of the co-segregation analysis to the G3 (n=62), G4 (n=31) and G5 
(n=55) mice revealed that: 65% of G3, 100% of G4 and 83% of G5 mice with renal 
papillary calcification were Brd4+/M149T, consistent with RCALC1 being an autosomal 
dominant disorder with reduced penetrance and likely due to a BRD4 mutation (Table 1). 
The effects of the BRD4-Met149Thr mutation on protein structure were therefore 
assessed in further detail.  
 
Characterization of the BRD4-Met149Thr variant on protein structure 
To assess the potential pathogenicity of the BRD4-Met149Thr variant we first examined 
online databases containing sequencing data from exome analysis in mice and humans. 
The BRD4-Met149Thr variant was absent from mouse populations, assessed using The 
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Jackson Laboratory database of exome sequencing data from 175 strains of mice(49), and 
human populations, assessed using the exome aggregation browser (ExAc), which 
contains genetic information on 60,706 individuals(50), thereby indicating that the BRD4 
Met149Thr variant is not a common polymorphism. The BRD4 Met149 residue is also 
highly evolutionarily conserved (Fig. 2C) and bioinformatic analysis using 
MutationTaster software(37) predicted the BRD4-Met149Thr variant to be damaging. We 
therefore next assessed the effect of the BRD4-Met149Thr variant on BRD4 protein 
structure. The BRD4 protein plays a critical role in transcriptional activation by binding 
to acetylated histone tails using its tandem bromodomains (BD) BD1 and BD2, and 
regulates transcription by recruiting proteins involved in nuclear remodelling using its 
extraterminal (ET) domain and its C-terminal interaction motif (CTM) (Fig. 2D)(51-54). 
The Met149 residue is located in the αC-helix of BRD4 BD1 (Fig. 2E), and previous 
studies have shown that Met149 is critical for histone binding, and that mutation to 
Ala149 impairs this binding(55). Structural modelling showed that the Met149 residue 
forms critical backbone contacts with three residues within αC (Fig. 2F), and likely plays 
a pivotal role in maintaining the structural integrity of BD1. Mutation to Thr149 is 
predicted to retain these contacts and form an additional polar contact with Asp145 (Fig. 
2G), which may reduce the flexibility of BD1. Thus, the BRD4-Met149Thr variant is 
likely to affect protein structure, and we therefore assessed the metabolic phenotype of 
mice with this mutation in further detail. 
 
Metabolic phenotype analysis of mice with the BRD4-Met149Thr mutation 
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Renal calcification is often associated with metabolic abnormalities including 
hypercalciuria, and we therefore performed biochemical analyses of plasma and urine 
samples from WT (Brd4+/+) and heterozygous mutant Brd4 (Brd4+/M149T) mice(1,6,7,56). 
Brd4+/M149T mice were fertile, grew at similar rates as their Brd4+/+ littermates, had 
similar body weights, and appeared morphologically normal. Analyses of plasma and 
urine samples from Brd4+/+ and Brd4+/M149T adult mice, aged 16 weeks, revealed no 
significant differences between Brd4+/+ and Brd4+/M149T mice in plasma concentrations of 
sodium, potassium, albumin-adjusted calcium, chloride, urea, creatinine, glucose, 
phosphate,  alkaline phosphatase activity, PTH or 25OHD (Table 2). Furthermore, there 
were no significant differences between Brd4+/+ and Brd4+/M149T mice in urine output or 
pH (Table 3). There were also no significant differences in the urinary excretion of 
calcium, phosphate, sodium, potassium, magnesium, urate, citrate or protein, which have 
previously been associated with renal calcification(57) (Table 3). An assessment of bone 
turnover showed no significant differences in plasma P1NP or urine CTx concentrations 
(Tables 2 and 3). Therefore, RCALC1 is a representative model for idiopathic renal 
calcification with no associated biochemical abnormality. 
 
Effect of the BRD4-Met149Thr mutation on gene transcription 
BRD4 plays a critical role in histone modification and gene transcription, and previous 
studies have shown that the Met149 residue is important for histone binding(55). We 
therefore hypothesised that the Brd4+/M149T mutation may lead to changes in gene 
transcription, which may explain the renal calcification phenotype observed in RCALC1 
mice. To assess gene transcription, we performed cDNA expression profiling using 
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whole kidneys from four Brd4+/M149T and eight Brd4+/+ mice from the parental strains (4 
BALB/c mice and 4 CH3 mice). We used kidneys as it was not possible to use 
microdissected specimens of calcified regions from the papilla, as these calcified regions 
had a mean diameter of 30.56μm (range 8 - 70μm) (sections from n = 63 mice), and the 
mean area of calcification was 725.83μm2 (range 50.24 – 3846.5 μm2), and therefore too 
small to extract high-quality RNA that would allow for the cDNA expression profiling 
studies. These analyses of kidneys revealed 37 genes to be significantly differentially 
expressed by at least 1.50-fold in Brd4+/M149T mice, when compared to Brd4+/+ mice 
(Table S3 and Table S4). Eighteen genes were significantly upregulated and 19 genes 
significantly downregulated in Brd4+/M149T kidneys, when compared to Brd4+/+ kidneys 
(Table S3 and S4). This included two genes involved in regulating vitamin D3 and 
calcium homeostasis. Thus, the vitamin D3-24-hydroxylase transcript cytochrome P450, 
family 24, subfamily A, polypeptide 1 (Cyp24a1), which encodes the 24-hydroxylase 
enzyme that degrades active 1,25-dihydroxyvitamin D3 to inactive vitamin D metabolites, 
was 5.05-fold higher in Brd4+/M149T kidneys, when compared with Brd4+/+ kidneys; 
whereas expression of the vitamin D binding protein (Gc, group-specific component) was 
1.55-fold lower in Brd4+/M149T kidneys, when compared to Brd4+/+ kidneys. Furthermore, 
qRT-PCR in kidneys from four Brd4+/+ and four Brd4+/M149T mice confirmed these results 
(Fig. 3A-B), thereby supporting the role of disturbed vitamin D metabolism in the 
etiology of the renal calcification observed in RCALC1 mice.                                                                                                                                 
 
A number of genes involved in cell survival and differentiation were also found to be 
differentially expressed in Brd4+/M149T kidneys, when compared to Brd4+/+ kidneys 
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(Table S3 and S4). The inhibitor of DNA binding 1 (Id1) and 3 (Id3) genes, which play a 
role in cell differentiation, were downregulated in Brd4+/M149T kidneys compared to 
Brd4+/+ (-3.91-fold for Id1 and -3.24-fold for Id3) (Table S3 and S4, Fig. 3C-D). In 
addition, genes involved in apoptosis were also differentially expressed. The gene 
encoding the pro-apoptosis protein caspase 3 (Casp3) was upregulated by 1.64-fold, 
while the cysteine-serine-rich nuclear protein 3 (Csrnp3), which is thought to have a role 
in transforming growth factor (TGF)-β-induced apoptosis(58) was downregulated by 1.60-
fold in Brd4+/M149T kidneys, when compared to Brd4+/+ kidneys (Table S3 and S4, Fig. 
4A-B). Previous studies of cultured renal cells and rat models of NL have suggested that 
apoptosis promotes adhesion and retention of calcium containing crystals(59-61), and 
because we had observed changes in expression of genes that are known to be important 
in apoptosis, we further sought to determine whether increased apoptosis was present in 
Brd4+/M149T kidneys. Apoptosis was assessed in serial sections from kidneys of 
Brd4+/M149T and Brd4+/+ mice using TUNEL staining, and von Kossa staining (Fig. 4C-
F). The percentage of apoptotic nuclei in the renal papillae of Brd4+/M149T mice (n=7) was 
not significantly different to that observed in Brd4+/+ mice (n=4) (1.13%±0.33% vs. 
3.36%±1.24%, respectively, t-test p>0.1). However, in 3 of the 7 kidneys from 
Brd4+/M149T mice examined, TUNEL-labelling was observed in interstitial regions of the 
renal papilla corresponding to sites of calcification (Fig. 4C, E), consistent with apoptosis 
of interstitial cells, which may comprise renal fibroblasts and immune cells(62). Such 
labelling was absent in the renal papillae of WT (Brd4+/+) mice (Fig. 4D, F). Therefore, 
Brd4+/M149T mice likely have increased apoptosis at sites of calcification within the renal 
papilla. 
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DISCUSSION 
Our studies have established a mouse model for an autosomal dominant form of renal 
calcification, designated RCALC1, which is due to a heterogeneous germline Met149Thr 
mutation of Brd4 and has phenotypic similarities to those observed in patients with NC(4). 
Thus, RCALC1 mutant mice (Brd4+/M149T) had the interstitial renal papillary calcium 
deposits that were similar to the papillary calcification that accompanies Randall’s 
plaque, a lesion observed in 85-95% of humans with calcium phosphate (apatite) and 
calcium oxalate deposits(4,5,46). Thus, in humans, Randall’s plaque have been reported to 
contain interstitial apatite deposits that act as a nidus for urothelial surface deposition of 
calcium oxalate(4,45), although calcium oxalate has been reported to overlie and adhere to 
Randall’s plaque in only 50% of stone formers(47). In addition, previous studies of plaque 
formation in patients with recurrent stones have demonstrated that most stones grow by 
remaining attached to papillae and that subsequent crystal deposition involves the stone-
tissue interface becoming overlaid with osteopontin and THP(4,44,46). This is consistent 
with observations that osteopontin is involved in the formation of organic layers of the 
plaques(45), and that molecules from the urine, such as THP, attach to these sites and 
extend the stone into the urinary space(44). Our findings that the RCALC1 (Brd4+/M149T) 
mice have calcification, detected by von Kossa staining, at the interstitial renal papilla 
that is colocalised with osteopontin and THP (Fig. 1), indicate that renal calcification in 
the Brd4+/M149T mice may involve a Randall’s plaque-like origin, similar to that observed 
in humans with NC(4,45). Thus, our findings suggest that the RCALC1 mutant mouse may 
represent a model for NC. Moreover, the RCALC1 mutant mice have similarities with 
other mouse models of NC, which also have interstitial papillary calcification, and these 
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include mice null for THP(63,64), osteopontin(63), and the sodium-hydrogen exchanger 
regulator factor 1 (NHERF1)(65). Furthermore, the absence of plasma and urinary 
biochemical abnormalities in the RCALC1 mice is also similar to that reported in 
osteopontin-null mice(63), whilst the lack of calcium oxalate deposits at the sites of 
papillary calcification in the RCALC1 mice is similar to that reported in the THP(63,64), 
osteopontin(63) and NHERF1(65) knockout mice. Thus, the RCALC1 mice, which have a 
Brd4 mutation, provide another model for studying the process of calcification in 
Randall’s plaques, that is observed in patients with NC (4,45). 
 
Our results, showing that a Brd4 mutation (Met149Thr) is associated with renal 
calcification in the RCALC1 mice, also reveal a new pathogenic role for the encoded 
protein, BRD4, which plays a critical role in regulating gene transcription by binding to 
modified histone tails of chromosomal DNA, and recruiting transcriptional activating 
proteins(51-54). Our structural studies demonstrated that mutation of Met149 to Thr149 is 
likely to affect protein structure (Fig, 2), and previous studies have shown the Met149 
residue to be required for histone binding(55). Furthermore, Met149 is highly conserved 
(Fig. 2), and the Thr149 mutation of this residue has not previously been identified in 
exome datasets from humans or mice, and co-segregates with the renal calcification 
phenotype. It is therefore likely that the mutation is pathogenic and is causative for the 
renal calcification in RCALC1 mice. Moreover, our cDNA expression profiling results 
showed that the BRD4-Met149Thr mutation resulted in altered expression of Cyp24a1 
and Gc, which are key genes in vitamin D metabolism and whose dysregulation in the 
kidneys (Fig. 3) may result in intracellular effects that cause renal calcification without 
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altering systemic calcium homeostasis (Table 2-3), as observed to occur in some patients 
with NC(4). Such underlying mechanisms that may cause renal calcification, without 
altering systemic calcium homeostasis, include cell survival, differentiation and 
apoptosis, and our cDNA expression profiling studies revealed: decreased expression of 
Id1 and Id3 (Fig. 3C-D), which have roles in cell differentiation; and altered expression 
of Casp3 and Csrnp3 (Fig. 4A-B), which have roles in apoptosis. Indeed, our studies of 
RCALC1 mice demonstrated that kidneys from the Brd4+/M149T mice had apoptosis of 
renal papillary interstitial cells in association with the calcified lesions (Fig. 4C-D). These 
results are consistent with those from other studies that have reported an increased 
apoptosis and differential expression of genes involved in proliferation in Randall’s 
plaques from stone formers when compared to a control group of patients(48). 
Furthermore, stone formation in rats is reported to be associated with an increase in 
apoptosis, and studies in renal cells have also shown that calcium phosphate stones are 
associated with apoptosis and changes in cell proliferation(48,66,67). Thus renal injury, and 
cell death may be common mechanisms in the etiology of renal calcification and the 
resulting NC and NL by generating sites that promote calcium crystal aggregation and 
growth(59,68).  
 
On the basis of these findings, we propose the following possible model for the 
interstitial renal papillary calcification and likely NC in RCALC1 mice. In the RCALC1 
Brd4+/M149T mice, the BRD4-Met149Thr mutation will impair gene transcription by 
affecting histone binding, which results in aberrant expression of genes encoding proteins 
involved in cell survival and differentiation that are known to be reliant on histone 
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modification(53). Failure of these pathways leads to increased apoptosis in renal papillary 
cells, and promotes tissue damage resulting in crystal retention and NC. In addition, 
dysregulation of the vitamin D metabolism pathway may result in intracellular toxic 
effects that exacerbate apoptosis(69). In summary, the RCALC1 mouse, which is 
associated with a BRD4 missense mutation, represents a model of idiopathic renal 
calcification that provides an in vivo resource for mechanistic studies of NC.  
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TABLES 
Table 1
 Co-segregation of Brd4+/M149T variant in RCALC1 mice 
 
 
 
 
 
 
The co-segregation of the Brd4+/M149T variant with renal calcification was investigated in 
four generations (G2-G5) of the RCALC1 mice. The Brd4 mutation co-segregated with 
the renal papillary calcification phenotype observed in RCALC1 mice over four 
generations. Between 72-93% of Brd4+/+ mice did not have renal papillary calcification.  
 
Genotype 
 
Generation 
 Renal Papillary Calcification 
  Present  Absent 
Brd4+/M149T  G2  50 (66%)  26 (34%) 
  G3  11 (65%)  6 (35%) 
  G4  13 (100%)  0 (0%) 
  G5  10 (83%)  2 (17%) 
Brd4+/+  G2  20 (26%)  56 (74%) 
  G3  8 (18%)  37 (82%) 
  G4  5 (28%)  13 (72%) 
  G5  3 (7%)  40 (93%) 
 30 
 
Table 2   Plasma biochemical studies of Brd4+/M149T mice 
 Male  Female 
 Brd4+/+  Brd4+/M149T  Brd4+/+  Brd4+/M149T 
 n=15  n=5  n=14  n=7 
Sodium (mmol/L) 155±3.3  154±1.1  152±2.3  151±2.4 
Potassium (mmol/L) 
 
7.26±0.9  7.52±1.5  7.33±0.8  6.91±0.8 
Calcium (mmol/L)a 2.43±0.2  2.35±0.1  2.46±0.1  2.35±0.1 
Chloride (mmol/L) 115±3.3  115±1.5  115±2.5  115±2.0 
Urea (mmol/L) 11.4±1.8  11.4±1.7  8.41±2.2  9.65±0.9 
Creatinine (µmol/L) 31.9±2.2  30.2±1.9  33.0±2.7  31.4±2.2 
Glucose (mmol/L) 7.49±1.6  7.78±1.5  8.62±0.5  9.52±0.7 
Phosphate (mmol/L) 2.15±0.5  2.01±0.6  2.40±0.6  1.79±0.4 
ALP (U/L) 59.7±15.6  64.2±9.6  101.8±20.5  93.0±14.8 
PTH (ng/mL) 52.5±7.8  36.4b 
  
 20.2±4.4  16.7±6.8 
25OHD (ng/mL) 43.0±2.4  32.5b  42.5±1.5  40.4±3.0 
P1NP (ng/mL) 23.1±1.5  22.1b  25.9±2.1  20.2±2.0 
Plasma biochemical analysis was performed on 16-week-old wild-type (Brd4+/+) and 
RCALC1 (Brd4+/M149T) mice. All values are expressed as mean±SD. ALP = alkaline 
phosphatase activity. aPlasma calcium concentrations were adjusted for the plasma 
albumin concentration. bPlasma biochemistry was obtained from n=3 male Brd4+/M149T 
mice. Mean values are shown in Table 2. All values from male Brd4+/M149T mice are 
within 2SD of the mean values for male WT mice. The individual values from male 
Brd4+/M149T mice are as follows: PTH - 34.3, 20.5 and 54.3 ng/mL; 25OHD - 29.5, 30.5 
and 37.4 ng/mL; P1NP - 22.2, 25.0 and 19.2 ng/mL.   
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Table 3  Urine biochemical studies of Brd4+/M149T mice 
 
 Male  Female 
 Brd4+/+  Brd4+/M149T  Brd4+/+  Brd4+/M149T 
 n=10-15  n=4  n=10-14  n=5-7 
Urine output (ml/24 hr) 2.35±1.03  2.63±1.98  2.16±2.03  1.84±0.53 
pH 6.96±0.60  7.07±0.42  6.74±0.77  6.37±0.24 
Calcium (µmol/24hr) 0.67±0.41  0.58±0.59  1.64±0.65  1.22±0.33 
Phosphate (mmol/24hr) 0.06±0.03  0.10±0.02  0.09±0.02  0.09±0.02 
Magnesium (µmol/24hr) 19.3±7.8  11.5±11.2  31.9±18.4  39±8.9 
Urate (µmol/24hr) 0.51±0.14  0.48±0.12  0.48±0.14  0.73±0.43 
Citrate (nmol/24hr) 5.2±3.3  3.0±1.4  2.6±0.6  2.7±0.9 
Sodium (mmol/24hr) 0.32±0.05  0.28±0.04  0.41±0.07  0.44±0.08 
Potassium (mmol/24hr) 0.58±0.09  0.47±0.06  0.75±0.10  0.80±0.10 
CTx (µg/24hr) 0.21±0.08  0.16±0.08  0.68±0.20  0.48±0.20 
Creatinine (µmol/24hr) 7.3±1.3  6.4±1.0  10.0±0.9  10.4±2.8 
Protein (mg/dl) 735.18±247.1
 
 884.36±389.2
 
 341.40±179.6
 
 395.3±158.1 
 
Urine biochemical analysis was performed on 16-week-old wild-type (Brd4+/+) and 
RCALC1 (Brd4+/M149T) mice, in metabolic cages, using urine samples collected over a 
24-hour period. All values are expressed as mean±SD. 
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FIGURE LEGENDS 
Fig. 1. Identification and characterization of RCALC1 mice 
 
(A) Radiograph of the 12-month old G1 founder male mouse showing renal opacity 
(arrow). Inset, an enlarged image of the renal opacity. (B-C)  Presence of renal 
calcification (brown) in (B) the cortex and (C) the interstitial regions of the renal papilla 
in kidney sections of G2 offspring, of the G1 founder male stained by von Kossa. (D-E) 
Renal calcification (brown) in (D) the cortex and (E) the collecting duct cells in kidney 
sections of wild-type (WT) C3H/HeH inbred mice, stained by von Kossa. (F-M) 
Immunofluorescence and von Kossa staining of serial sections of kidneys from an 
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RCALC1 mouse and an unaffected WT littermate. (F-I) Osteopontin (OPN) and von 
Kossa staining, showing colocalization of OPN staining (green, white arrows) with areas 
of interstitial calcification in RCALC1 mice (black arrows), that was not observed to 
occur in WT mice. (J-M) Tamm-Horsfall protein (THP) and von Kossa staining, showing 
the presence of THP (orange, asterisks) in renal thick ascending limbs of RCALC1 and 
WT mice. THP immunostaining and von Kossa staining, corresponding to intersititial 
calcification, colocalize (arrow) in RCALC1 mice. Scale bars = 50µm.  
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Figure 2.  Identification of the Brd4-Met149Thr mutation in RCALC1 mice  
 
(A) Haplotype analysis of 51 G2 mice. Each box represents the genotype for the 
polymorphic locus. Filled box, BALB/c allele; open box, C3H allele. The number of 
mice that had each haplotype is indicated below each column. Analysis localized the 
RCALC1 locus to a ~15Mbp region on mouse chromosome 17, flanked by rs33663699 
and D17Mit51. (B) DNA sequence analysis of Brd4 in DNA extracted from an unaffected 
(wildtype, WT) and an RCALC1 mouse (mutant) confirmed the whole-exome analysis 
result of a heterozygous T-to-C transition in codon 149 in RCALC1 mice, that was 
predicted to result in a missense change of a WT methionine (Met, M) to a mutant 
threonine (Thr, T). (C) Multiple protein sequence alignment of residues comprising the 
αAZ, αA, αB and αC helices that form bromodomain 1 (BD1) of BRD4 in five species. 
Conserved residues are shown in gray, and WT (Met, M) and mutant (Thr, T) residues in 
red. (D) Domain structure of human BRD4 protein, which comprises two bromodomains 
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(BD1 and BD2), an extraterminal (ET) domain and a carboxy-terminal motif (CTM). (E) 
Structure of the human BRD4 bromodomain 1 (PDB:5LRQ) with Met149 indicated in 
blue. (F) Close-up view of the wild-type Met149 residue showing backbone polar 
contacts with three residues, Asp146, Ala152 and Leu153. (G) The mutant Thr149 
(purple) retains these contacts, but forms an additional contact with residue Asp145, 
which may reduce flexibility of the BRD4 protein, and thereby affect its function.  
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Figure 3.  Analysis of Differentially Expressed Genes by qRT-PCR  
 
(A-D) Validation of differentially expressed genes from cDNA expression profiling 
analysis of kidneys from wild-type (Brd4+/+) and RCALC1 (Brd4+/M149T) mice by qRT-
PCR analysis. Renal expression of: (A) Cyp24a1, (B) Gc, (C) Id1, and (D) Id3, in cDNA 
from Brd4+/+ and Brd4+/M149T mice. N=4-6 mice per group. Data was normalized to 
geometric mean of 3 housekeeper genes (Ccnd1, Ccnd2, Gapdh) and expressed as a fold-
change relative to Brd4+/+, set at 1. Histograms are presented as mean±SEM. Statistical 
analyses were performed by Student’s t-test, *p<0.05, **p<0.02, compared to Brd4+/+.  
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Fig. 4 Analysis of apoptosis in Brd4+/M149T mice 
 
(A-B) Validation of differentially expressed genes involved in apoptosis from cDNA 
expression profiling analysis of kidneys from wild-type (Brd4+/+) and RCALC1 
(Brd4+/M149T) mice by qRT-PCR analysis. Renal expression of: (A) Casp3 and (B) 
Csrnp3 genes, in kidney cDNA from Brd4+/+ and Brd4+/M149T mice. N=4-6 mice for each 
group. Data was normalized to the geometric mean of three housekeeper genes (Ccnd1, 
Ccnd2, Gapdh) and expressed as a fold-change relative to Brd4+/+, set at 1. Histograms 
are presented as mean±SEM. Statistical analyses were performed by Student’s t-test, 
*p<0.05, **p<0.02, compared to Brd4+/+. (C-D) TUNEL and (E-F) von Kossa staining 
showing apoptotic nuclei (green) in areas corresponding to interstitial calcification in 
RCALC1 (Brd4+/M149T) mice (arrows) and in control wild-type (WT) Brd4+/+ mice. 
Nuclei were counterstained with nuclear fast red for von Kossa staining and DAPI (blue) 
for immunofluorescence. Scale bars = 50µm. 
 
 38 
